|
|
|
| Effects on Cell Viability of HUVECs Stimulated by Serum From Children with Coronary Artery Lesions of Kawasaki Disease via Regulating PAI-1 |
| YU Lin, CHEN Mingqun, et al |
| Leshan Downtown District People's Hospital, Sichuan Leshan 614000, China |
|
|
|
|
Abstract Objective: To investigate the effect and mechanism of serum from children with coronary artery lesions of Kawasaki disease on the viability of human umbilical vein endothelial cells (HUVECs) by regulating PAI-1. Methods: Fifty-two children with Kawasaki disease were collected, including 25 children with coronary artery injury, 27 children with non-coronary artery injury, and 21 children with healthy control group. Clinical data were collected to detect the high risk of KD-CALs and coagulation index, and serum samples were prepared. Human umbilical vein endothelial cells (HUVECs) were treated with serum for 24 hours. The expression of PAI-1 in HUVECs was detected by RT-qPCR and the cell viability was detected by CCK-8. Results: Platelet, white blood cell (WBC), erythrocyte sedimentation rate (ESR), prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen (FIB) and fibrinogen degradation product (FDP) levels in children with Kawasaki disease complicated with coronary artery injury were significantly higher than those in the control group. Conclusion: Children with KD-CALs have significantly elevated levels of serum PAI-1 in a massive hypercoagulable state, and increased PAI-1 levels in HUVECs leading to the inhibition of viability of HUVECs.
|
|
|
|
|
|
[1] Liu YC, Lin MT, Wang JK, et al. State-of-the-art acute phase management of kawasaki disease after 2017 scientific statement from the American Heart Association [J]. Pediatr Neonatol,2018,1875~9572(17):30592.
[2] Kuo HC. Dissecting Kawasaki disease: a state-of-the-art review [J]. Eur Pediatr,2017,176(8): 995~1009.
[3] Kitamura S. Pediatric coronary artery revascularization surgery: development and effects on survival, cardiac events and graft patency for children with kawasaki disease coronary involvements [J]. Iran Pediatr,2016, 26(1): e3875.
[4] Lu WH, Huang SJ, Yuh YS, et al. Platelet endothelial cell adhesion molecule-1 gene polymorphisms are associated with coronary artery lesions in the chronic stage of Kawasaki disease [J]. Acta Cardiol Sin,2017, 33(3): 273~284.
[5] Duan C, Du ZD, Wang Y, et al. Effect of pravastatin on endothelial dysfunction in children with medium to giant coronary aneurysms due to Kawasaki disease [J]. World Pediatr,2014,10(3):232~237.
[6] Luo M, Ji Y, Luo Y, et al. Plasminogen activator inhibitor-1 regulates the vascular expression of vitronectin[J].Thromb Haemost,2017, 15(12):2451~2460.
[7] Japanese Circulation Society Joint Research Group. Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease [J].Pediatrics Internation,2005, 47(6):711~732.
[8] Furuyama H, Odagawa Y, Katoh C, et al. Altered myocardial flow reserve and endothelial function late after Kawasaki disease [J]. Pediatr,2003, 142(2): 149~154.
[9] 王成.小儿心血管病手册[M].北京人民军医出版社,2002.418~424.
[10] Rebalka IA, Raleigh MJ, D'Souza DM, et al. Inhibition of PAI-1 Via PAI-039 improves dermal wound closure in diabetes [J]. Diabetes,2015,64(7):2593~2602. |
|
|
|
2018, Vol. 24 
